The Food and Drug Administration (FDA) performed an inspection at Labryo Fertility Center in Newport Beach on March 26, focusing on human cellular, tissue, and gene therapies, according to data posted on the FDA’s website.
The summary of the inspection showed no corrective actions were recommended for Labryo Fertility Center’s management operations.
The FDA regularly conducts inspections of facilities across the country to ensure the workplace and products meet laws and regulations designed to support public health. Findings from these inspections are released to the public.
According to its website, the FDA is a federal agency chiefly in charge of regulating the production and distribution of human and animal drugs, biological products, medical devices and tobacco products, ensuring their safety and quality.
Information in this article was obtained from the U.S. Food and Drug Administration. The source data can be found here.
